Secure Remote Access for the Pharma and Life Sciences Sector

Safous Privileged Remote Access for Research & Manufacturing

The pharmaceutical and life sciences industry is racing to modernize. Connected devices, cloud platforms, AI-driven research tools, and distributed collaboration networks are transforming how organizations discover drugs, conduct clinical trials, and manufacture medicines. Yet this digital acceleration comes with a cost: exponentially more entry points for attackers to exploit.

Intellectual property, including drug formulations, clinical trial designs, and manufacturing processes, represents decades of research investment – and cybercriminals are hunting for it. But when attackers target these critical IT and OT systems, they don't just steal data; they disrupt production timelines, delay drug approvals, and jeopardize patient safety.

Across ASEAN and globally, cybersecurity and data protection regulations increasingly require stronger control over remote access, privileged accounts, and third-party connections in regulated industries. Organizations must demonstrate centralized oversight, auditable session logging, and accountability across jurisdictions, yet these compliance mandates often conflict with the flexibility research and manufacturing teams need to innovate efficiently.

Most modern breaches begin with exposed remote services and compromised credentials. Attackers move from remote access to privilege escalation, then laterally across environments – ultimately disrupting research operations and manufacturing systems.

Safous Privileged Remote Access bridges this gap. Purpose-built to secure IT and OT environments, it combines privileged access management, identity and access management, and zero-trust network access into a unified platform – protecting IP and strengthening compliance efforts without introducing complexity to networks.

Pharma and Life Sciences Security Risks

As the industry accelerates digital transformation, risk accelerates too. Check out these findings from the 2026 Deloitte Life Sciences Outlook:[1]

48% of execs say digital transformation will likely have a substantial impact on their organizations.

35% say cybersecurity concerns will affect their digital transformation strategy.

80% believe AI will be a key growth driver for life sciences organizations.

51% report that new regulatory requirements will have the biggest strategic impact this year.

[1] https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html

Case Study: Global Pharma Manufacturing Organization

Scope:
12 research sites +
8 manufacturing facilities across North America and EMEA

Users:
500 researchers, 200 manufacturing technicians, 150 third-party vendors and contractors

The Need:
Secure remote access to manufacturing systems, research platforms, and clinical trial data repositories across geographically dispersed facilities

Challenges:

- Required auditable access for vendors and remote researchers without adding VPNs or overhauling legacy equipment
- Lacked centralized oversight of who accessed sensitive IP and clinical trial data
- Multiple tools created compliance gaps and operational overhead

Outcomes:

- Agentless remote access across all environments without added complexity
- Centralized visibility of all privileged and remote access sessions
- Time-bound, supervised vendor access
- Reduced reliance on traditional VPN exposure
- Unified, tamper-evident audit logs
- Improved audit readiness across global and regional regulatory frameworks

How Safous Helps

Secure Research Collaboration:
Enable researchers across multiple sites to securely access research platforms, databases, and analytical tools without exposing sensitive data or clinical trial information to unauthorized users.

Third-Party System Access:
Allow technicians and third-party vendors to access legacy manufacturing equipment and OT systems for maintenance and support without agents, network changes, or VPN complexity.

Session Oversight:
Real-time alerts, supervised access, and time-bound permissions prevent misuse of privileged accounts and ensure every access to sensitive systems is recorded, traceable, and auditable.

Intellectual Property Protection:
Prevent unauthorized access to drug formulations, clinical trial designs, and proprietary manufacturing processes through identity-based, least-privilege access controls.

Compliance-Ready Logging:
Capture privileged sessions in real time to support security control requirements aligned with HIPAA, 21 CFR Part 11, GDPR, ISO 27001, and regional cybersecurity and data protection regulations, including ASEAN PDPA frameworks and national Cybersecurity Laws.

Fast Time to Value:
A single subscription fee includes all security features, no add-ons needed. And with only one outbound App Gateway to deploy, organizations can go live in 3–5 days without disrupting operations.

Secure Pharma and Life Sciences Operations With Safous

Safous provides identity-based, agentless remote access for IT and OT environments with a globally proven Zero Trust platform, making it easier for pharmaceutical and life sciences organizations to control remote and privileged access while protecting research and manufacturing.

GET STARTED TODAY.